Prevalence of small airway dysfunction in the Swiss PneumoLaus Cohort.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
09
06
2023
accepted:
03
07
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
Recent evidence identified exposure to particulate matter of size ≤2.5 µm (PM SAD was defined as a maximum mid-expiratory flow (MMEF) <65% of predicted value (PV) or MMEF <lower limit of normal (LLN) measured by spirometry in the Swiss PneumoLaus cohort. We performed bivariate and multivariable analysis with MMEF criteria, age, sex, body mass index, respiratory symptoms and smoking status. Mean PM Among 3351 participants (97.6% Caucasian, 55.7% female sex, mean age 62.7 years), we observed MMEF <65% PV in 425 (12.7%) and MMEF <LLN in 167 (5.0%) individuals. None of the participants had both MMEF <LLN and ≥65% PV. MMEF <65% PV and MMEF <LLN were significantly associated with age, smoking status, cough, sputum and dyspnoea, whereas a positive association with MMEF <65% PV was observed for individuals aged >65 years only. In an area where ambient PM The observed low prevalence of SAD of 5.0-12.7% depending on criteria employed may be related to lower PM
Sections du résumé
Background
UNASSIGNED
Recent evidence identified exposure to particulate matter of size ≤2.5 µm (PM
Methods
UNASSIGNED
SAD was defined as a maximum mid-expiratory flow (MMEF) <65% of predicted value (PV) or MMEF <lower limit of normal (LLN) measured by spirometry in the Swiss PneumoLaus cohort. We performed bivariate and multivariable analysis with MMEF criteria, age, sex, body mass index, respiratory symptoms and smoking status. Mean PM
Results
UNASSIGNED
Among 3351 participants (97.6% Caucasian, 55.7% female sex, mean age 62.7 years), we observed MMEF <65% PV in 425 (12.7%) and MMEF <LLN in 167 (5.0%) individuals. None of the participants had both MMEF <LLN and ≥65% PV. MMEF <65% PV and MMEF <LLN were significantly associated with age, smoking status, cough, sputum and dyspnoea, whereas a positive association with MMEF <65% PV was observed for individuals aged >65 years only. In an area where ambient PM
Conclusions
UNASSIGNED
The observed low prevalence of SAD of 5.0-12.7% depending on criteria employed may be related to lower PM
Identifiants
pubmed: 37701366
doi: 10.1183/23120541.00381-2023
pii: 00381-2023
pmc: PMC10493711
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of Interest: J. Vaucher reports receiving grants or contracts from Swiss National Science Foundation grant 3247730_204523, Fondation Leenaards, AGLA funding and Fondation pour la Recherché Contre le Diabète, outside the submitted work. Conflict of interest: C. von Garnier reports grants or contracts from OM Pharma, outside the submitted work; consulting fees from AstraZeneca, GSK, Boehringer Ingelheim and OM Pharma, outside the submitted work; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, GSK and OM Pharma, outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.
Références
Acta Med Scand. 1963 Feb;173:193-8
pubmed: 13968399
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
J Heart Lung Transplant. 2012 Dec;31(12):1288-92
pubmed: 23102913
Eur Clin Respir J. 2014 Oct 17;1:
pubmed: 26557240
Int J Chron Obstruct Pulmon Dis. 2020 Nov 12;15:2913-2921
pubmed: 33209020
Chest. 2006 Feb;129(2):369-377
pubmed: 16478854
Respir Care. 2020 Sep;65(9):1392-1412
pubmed: 32209703
Eur Respir J. 2022 Jul 13;60(1):
pubmed: 34949706
BMJ Open Respir Res. 2020 Dec;7(1):
pubmed: 33371011
Chest. 2021 Jul;160(1):114-134
pubmed: 33819471
Lancet Respir Med. 2022 Jul;10(7):661-668
pubmed: 35247313
Respir Med. 2016 Jul;116:19-27
pubmed: 27296816
Lancet Respir Med. 2020 Nov;8(11):1081-1093
pubmed: 32598906
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Thorax. 2023 Mar;78(3):274-280
pubmed: 35361688
Eur J Epidemiol. 2015 Aug;30(8):661-708
pubmed: 26386597
Eur Respir J. 2015 May;45(5):1283-92
pubmed: 25537554
J Heart Lung Transplant. 1996 Feb;15(2):175-81
pubmed: 8672521
Am J Med. 1972 Jun;52(6):725-37
pubmed: 5030170
Eur Respir J. 2010 Aug;36(2):277-84
pubmed: 20075056
Lancet Respir Med. 2018 Aug;6(8):591-602
pubmed: 30072106
Am Rev Respir Dis. 1991 Nov;144(5):1202-18
pubmed: 1952453
Lancet Glob Health. 2023 Jan;11(1):e69-e82
pubmed: 36521955
Thorax. 2018 Apr;73(4):376-384
pubmed: 29306902
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Eur Respir J. 2017 Nov 30;50(5):
pubmed: 29191952
J Asthma. 2021 Mar;58(3):326-333
pubmed: 31820665
Eur Respir J. 2012 Jun;39(6):1458-67
pubmed: 22267757
Chronic Obstr Pulm Dis. 2015 Mar 10;2(2):94-102
pubmed: 28848835
Respir Res. 2018 Dec 13;19(1):250
pubmed: 30545344
Soz Praventivmed. 1997;42(2):67-84
pubmed: 9151378
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Nutrients. 2019 Feb 03;11(2):
pubmed: 30717453
Respir Res. 2022 Mar 21;23(1):67
pubmed: 35313875
J Thorac Dis. 2017 Nov;9(11):4538-4549
pubmed: 29268524
Lancet Respir Med. 2020 Nov;8(11):1062-1063
pubmed: 32598905
Respir Med. 2019 Sep;156:58-68
pubmed: 31437649
BMC Cardiovasc Disord. 2008 Mar 17;8:6
pubmed: 18366642
Int J Cardiol. 2017 Jan 15;227:727-733
pubmed: 27816302